Page 42 - Alkermes News Today

StockNews.com downgraded shares of Alkermes (NASDAQ:ALKS – Get Rating) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday morning. A number of other brokerages have also recently issued reports on ALKS. JPMorgan Chase & Co. dropped their price target on shares of Alkermes from $33.00 to $29.00 […]

/PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal biology and neuronal health to develop...

Durvalumab, tremelimumab, and chemotherapy can produce durable responses in newly diagnosed, advanced-stage epithelial ovarian cancer.

Item 1.01 Entry into a Material Definitive Agreement. Amendment No. 5 to Credit Agreement On March 29, 2023 , Baudax Bio, Inc. entered into that certain Amendment No. 5 and Consent to Credit... | April 4, 2023

Alkermes (NASDAQ:ALKS – Get Rating) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday. Other equities research analysts have also issued research reports about the company. HC Wainwright restated a “neutral” rating and issued a $32.00 price objective on shares of Alkermes […]

Shares of Alkermes plc (NASDAQ:ALKS – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price […]

The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

(BPT) - The story you are about to read may not be representative of all people living with schizophrenia. The opinions expressed here are those of Robert, a person living

Response rates were superior to those seen with other single agents in patients with platinum-resistant disease and tumors positive for folate receptor alpha.

An analysis of postmortem records showed fewer suicides among individuals with schizophrenia who were taking clozapine, an underutilized antipsychotic, compared to those taking other antipsychotics.